Podcasts about Roche

In this special three-part series on the recent consistory, Father McTeigue begins an examination of the questionable claims made by Cardinal Roche about the liturgy. Father finishes with Weekend Readiness to prepare you for Sunday Mass. Show Notes ENGLISH EXCLUSIVE: Cardinal Roche Defends Traditionis Custodes at Extraordinary Consistory  Bishop Athanasius Schneider: Cardinal Roche's Liturgy Report Is “Manipulative” and Distorts History  Does 'Traditionis Custodes' Pass the Juridical Rationality Test? – Os Justi Press  The Latin Mass and the Intellectuals: Petitions to Save the Ancient Mass from 1966 to 2007 Ottaviani Intervention (1969) | Latin Mass Society  The text Card. Roche gave the other Cardinals about the TLM, ‘Traditionis custodes' and “unity” during the recent consistory: an examination of “The Roche Report” | Fr. Z's Blog  The Church Speaks to the Modern World: The Social Teachings of Leo XIII | Etienne Gilson Has the new liturgy changed you? | Charlotte was Both Franz Kafka, Nancy Drew and Charlie Parker Become Free to Use Ahead Of March For Life, Trump Admin Ends Funding For Research Using Aborted Baby Tissue Third Sunday in Ordinary Time | USCCB iCatholic Mobile The Station of the Cross Merchandise - Use Coupon Code 14STATIONS for 10% off | Catholic to the Max Read Fr. McTeigue's Written Works! "Let's Take A Closer Look" with Fr. Robert McTeigue, S.J. | Full Series Playlist Listen to Fr. McTeigue's Preaching! | Herald of the Gospel Sermons Podcast on Spotify Visit Fr. McTeigue's Website | Herald of the Gospel Questions? Comments? Feedback? Ask Father!

Zur Niederschlagung der Protestbewegung im Iran nahm das Mullah-Regime in den letzten Tagen und Wochen tausende von Toten in Kauf. Die genaue Anzahl der Opfer ist weiterhin unklar. Nun beschäftigte sich der UNO-Menschenrechtsrat in Genf in einer Sondersitzung mit der Gewalt im Iran. Alle Themen: (00:00) Intro & Schlagzeilen (01:05) UNO wirft Führung im Iran «brutale Unterdrückung» vor (05:22) Nachrichtenübersicht (09:52) «Die humanitäre Not wurde am WEF kaum beachtet» (15:44) Medikamentenpreise: Quo vadis Roche und Novartis? (21:24) Milde Urteile im Genfer Motorradbanden-Prozess (26:05) Wie Russland ukrainische Kinder zu seinen Soldaten macht (33:07) Ist Spaniens Schienennetz noch sicher? (37:44) Rückblick auf die Ära Winfried Kretschmann

Who's on your bench? When you're building a Childfree life on your own terms, the professionals and teammates you surround yourself with make all the difference in how well you age.In this episode, Maddy Roche and Bri Conn, CFP®, walk through the essential people you need in your corner, from certified financial planners who understand Childfree planning to aging care managers who can help you navigate long-term care. They tackle why estate planning is more complex when you don't have a next generation to handle decisions, how Childfree Trust® provides a professional fiduciary solution, and why outsourcing the right things frees you to focus on what matters most.Key Takeaways:CFP® professionals are fiduciaries legally obligated to act in your best interest, and finding one who understands how being Childfree fundamentally changes your financial picture ensures you get advice that actually fits your goals.Medical power of attorney, financial power of attorney, executor, and trustee are essential positions that take time to fill, especially when you don't have a next generation to rely on.Childfree Trust® provides a professional fiduciary solution. Acting in all 50 states as any of the four key estate planning roles, Childfree Trust® can serve as your primary choice or backup option, giving your existing representatives the gift of being able to transfer responsibility if needed.Whether it's tax preparation, home maintenance, or health management, identifying what you can delegate to professionals frees you to spend time with people and activities you actually care about.Primary care doctors, aging care managers, personal trainers, and community leaders all play a role in preventing issues before they arise and ensuring you have advocates when you need them.Episode Hosts:Maddy Roche - Chief Growth Officer at Childfree Trust® and responsible for all sales & marketing initiatives.Bri Conn, CFP® - Customer Experience Manager at Childfree Trust® and co-host. Bri understands firsthand that the CFP® curriculum doesn't address Childfree planning.About Childfree Life by Design: Childfree Life By Design is dedicated to helping Childfree individuals thrive by providing resources, guidance, and community. We recognize that when you've made a decision roughly 75% of the population doesn't make, conventional wisdom simply doesn't apply to you. Our mission is to help you design a life that works for you, covering everything from finances and relationships to career decisions and building support networks that will actually be there when you need them. Connect with Us: Ready to design your ideal Childfree life? Connect with our financial planning team at childfreewealth.com or learn more about estate planning at childfreetrust.com Join the conversation on social media: Instagram: https://www.instagram.com/childfreeinsightsFacebook: https://www.facebook.com/ChildfreeInsights/LinkedIn: https://www.linkedin.com/company/childfreeinsightsYouTube: https://www.youtube.com/@ChildfreeInsights Disclaimer: This podcast is for educational & entertainment purposes. Please consult your advisor before implementing any ideas heard on this podcast...

Dominic Pappalardo, chief multi-asset strategist at Morningstar Wealth, discusses the firm's outlook for 2026, noting that the market has rewarded the sellers of artificial intelligence technologies, but at some point the buyers of AI technology will "need to show material gains from those investments" to justify the spending and maintain AI profits. As a result, he is cautious on artificial intelligence and technology stocks, but he is positive on the market and says he expects to see strong opportunities in small-cap stocks and international plays, particularly in emerging markets. Cullen Roche discusses his new book, "Your Perfect Portfolio: The Ultimate Guide to Using the World's Most Powerful Investment Strategies," which examines what it takes to apply some of the most famous investment strategies of all time to an individual investment portfolio, and what to expect for results. Roche, who is founder and chief investment officer of the Discipline Funds, also discusses why it is more important for investors to focus on "you" rather than on "perfect." Plus Todd Rosenbluth, head of research at VettaFi, revisits a fund that he made the ETF of the Week last year to give it the honor again. Repeats are rare in ETF of the Week history, but results alone might deserve it here; the fund he picked — tied to cryptocurrency — has had three stellar calendar years and is already up more than 33 percent for the first few weeks of 2026.  

In this episode of Words on a Wire, host Will Rose speaks with historian Jeff Roche, author of The Conservative Frontier: Texas and the Origins of the New Right (University of Texas Press), about how West Texas became one of the most conservative regions in American political life. Roche traces the roots of modern conservatism back to the late nineteenth century, beginning with the rise of ranching culture after the displacement of Indigenous peoples and the collapse of the bison economy. He explains how the entrepreneurial, anti-state ethos of early ranchers—embodied by figures like Charles Goodnight—combined with the mythology of the cowboy to form a durable regional identity centered on self-reliance, individualism, and suspicion of government authority.The conversation also explores the defining role of geography and environment in shaping West Texas culture, from its flat, arid plains to its chronic vulnerability to drought. Roche highlights the Dust Bowl as a turning point that shattered faith in agricultural abundance while deepening resentment toward federal intervention. The episode concludes with a discussion of Barry Goldwater's influence on the rise of the New Right, showing how West Texas conservatives helped redefine American conservatism in the mid-twentieth century and laid the groundwork for the modern Republican Party.

The CPG Guys are joined in this episode by Liz Roche, VP for Media and Measurement at Albertson's Media Collective, the retail media division of the Albertsons Companies.This episode was recorded in Las Vegas Nevada at CES 2026.Find Liz Roche on Linkedin at : https://www.linkedin.com/in/eroche1/Find AMC on Linkedin at : https://www.linkedin.com/company/albertsons-media-collective/Find AMC online at : https://albertsonsmediacollective.com/Here's what we asked her:Liz, you've just crossed the one-year mark leading measurement and media at Albertsons Media Collective. Looking back, what surprised you most about the role—and what are you most proud of accomplishing in year one?In-store retail media has become one of the most talked-about topics in the industry. Why was it so important for Albertsons Media Collective to lean in here—and what problem were you trying to solve first?You first announced your in-store efforts at Cannes, and now at CES you're sharing pilot results. What did those pilots validate—and what did they challenge in your original assumptions?You've highlighted a Mondelez and Sargento case study—what made those partners a strong fit for in-store activation, and what outcomes should brands be paying attention to?From a retailer perspective, what does it actually take to scale in-store retail media without compromising the shopper experience or store operations?You've been very vocal about transparent measurement. Why is that such a critical foundation for retail media relationships, especially as in-store and offsite continue to grow?Albertsons Media Collective has done some creative things—like the BOGO Blitz with enterprise media match and the Alby Awards with guaranteed ROAS. What was the thinking behind rewarding performance in these ways?As we look toward 2026, how do you see measurement evolving—especially across in-store, onsite, and offsite—and what should brands and retailers be preparing for now?You're showcasing future-state demos here at CES. Without giving too much away, what should the industry be excited about when it comes to where in-store and retail media are headed?For brands and retailers listening who want to be ready for what's next in retail media, what's the one mindset shift—or capability—they need to start building today?CPG Guys Website: http://CPGguys.comFMCG Guys Website: http://FMCGguys.comSheCOMMERCE Website: https://shecommercepodcast.com/Rhea Raj's Website: http://rhearaj.comLara Raj in Katseye: https://www.katseye.world/DISCLAIMER: The content in this podcast episode is provided for general informational purposes only. By listening to our episode, you understand that no information contained in this episode should be construed as advice from CPGGUYS, LLC or the individual author, hosts, or guests, nor is it intended to be a substitute for research on any subject matter. Reference to any specific product or entity does not constitute an endorsement or recommendation by CPGGUYS, LLC. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent.CPGGUYS LLC expressly disclaims any and all liability or responsibility for any direct, indirect, incidental, special, consequential or other damages arising out of any individual's use of, reference to, or inability to use this podcast or the information we presented in this podcast.

This document is revealing and is likely the TLM roadmap for this pontificate.Sponsored by Fidei Email:https://www.fidei.emailSources:https://www.returntotradition.orgorhttps://substack.com/@returntotradition1Contact Me:Email: return2catholictradition@gmail.comSupport My Work:Patreonhttps://www.patreon.com/AnthonyStineSubscribeStarhttps://www.subscribestar.net/return-to-traditionBuy Me A Coffeehttps://www.buymeacoffee.com/AnthonyStinePhysical Mail:Anthony StinePO Box 3048Shawnee, OK74802Follow me on the following social media:https://www.facebook.com/ReturnToCatholicTradition/https://twitter.com/pontificatormax+JMJ+#popeleoXIV #catholicism #catholicchurch #catholicprophecy#infiltration

Want to reach out to us? Want to leave a comment or review? Want to give us a suggestion or berate Anthony? Send us a text by clicking this link!Want the truth about where the trad world stands—without the coping or the clickbait? We follow the threads from Bishop Fulton Sheen's long-delayed beatification, through Cardinal Roche's letter on the liturgy, to the uncomfortable reality that a so-called youth movement has quietly gone gray.We get honest about what younger men are actually dealing with: a wrecked dating market, credential mills, debt-squeezed housing, and a job landscape warped by visas and offshoring. Against those pressures, endless arguments about documents and labels feel like theater. Tradition doesn't need to be softer—it needs to be lived. Less quote-mining, more discipline. Less outrage, more parish life. Teach a traditional Catholic life. Live it for a century. Then evaluate the council when the smoke clears.We dive into Roche's claim that the older books were a concession never intended to grow and hold it up to Benedict's “mutual enrichment.” On the ground, where both forms coexist, reverence improves, and people discover the old rite without fleeing their parishes. That matters more than any memo. We also sit with Fulton Sheen's “ape of the Church,” why hindsight on Vatican II is tricky, and why Sheen still draws seekers who are hungry for clarity and beauty.Finally, we talk about Scott Adams and the risk of treating salvation like a hack. Baptism, repentance, confession, and real community are not optional extras. The Sunday obligation protects the habit of belonging when screens tempt us to go it alone. If beauty saves, it does so in the flesh: Mass, meals, laughter, and the steady weight of shared prayer.Join us for a candid, hopeful reset. Subscribe, share with a friend who needs this conversation, and leave a review to help more people find the show. Then tell us: what should a real trad rebrand look like where you live?Support the showTake advantage of great Catholic red wines by heading over to https://recusantcellars.com/ and using code "BASED" for 10% off at checkout!********************************************************Please subscribe! https://www.youtube.com/channel/UCKsxnv80ByFV4OGvt_kImjQ?sub_confirmation=1https://www.avoidingbabylon.comMerchandise: https://avoiding-babylon-shop.fourthwall.comLocals Community: https://avoidingbabylon.locals.comFull Premium/Locals Shows on Audio Podcast: https://www.buzzsprout.com/1987412/subscribeRSS Feed for Podcast Apps: https://feeds.buzzsprout.com/1987412.rssRumble: https://rumble.com/c/AvoidingBabylon

January 14th, 2026 - We welcome back Jordan Pacheco to discuss the Consistory and Cardinal Roche's screed on liturgical "reform". TheStationOfTheCross.com/ACT

Dr. Hope Rugo and Dr. Vivek Subbiah discuss innovative trial designs to enable robust studies for smaller patient populations, as well as the promise of precision medicine, novel therapeutic approaches, and global partnerships to advance rare cancer research and improve patient outcomes. TRANSCRIPT  Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center [in Los Angeles]. The field of rare cancer research is rapidly transforming thanks to progress in clinical trials and treatment strategies, as well as improvements in precision medicine and next-generation sequencing that enable biomarker identification. According to the National Cancer Institute, rare cancers occur in fewer than 150 cases per million each year, but collectively, they represent a significant portion of all cancer diagnoses. And we struggle with the appropriate treatment for these rare cancers in clinical practice. Today, I am delighted to be joined by Dr. Vivek Subbiah, a medical oncologist and the chief of early-phase drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Subbiah is the lead author of a paper in the ASCO Educational Book titled "Designing Clinical Trials for Patients with Rare Cancers: Connecting the Zebras," a great title for this topic. He will be telling us about innovative trial designs to enable robust studies for small patient populations, the promise of precision medicine, and novel therapeutic approaches to improve outcomes, and how we can leverage AI now to enroll more patients with rare cancers in clinical trials. Our full disclosures are available in the transcript of this episode.  Dr. Subbiah, it is great to have you on the podcast today. Thanks so much for being here. Dr. Vivek Subbiah: Thank you so much, Dr. Rugo, and it is an honor and pleasure being here. And thank you for doing this podcast for rare cancers. Dr. Hope Rugo: Absolutely. We are excited to talk to you. And congratulations on this fantastic paper. It is such a great resource for our community to better understand what is new in the field of rare cancer research. Of course, rare cancers are complex and multifaceted diseases. And this is a huge challenge for clinical oncologists. You know, our clinics, of course, cannot be designed as we are being very uni-cancer focused to just be for one cancer that is very rare. So, oncologists have to be a jack of all trades in this area. Your paper notes that there are approximately 200 distinct types of rare and ultra-rare cancers. And, by definition, all pediatric cancers are rare cancers. Of course, clinical trials are essential for developing new treatment strategies and improving patient outcomes, and in your paper, you highlight some unique challenges in conducting trials in this rare cancer space. Can you tell us about the challenges and how really innovative trial designs, I think a key issue, are being tailored to the specific needs of patients with rare cancer and, importantly, for these trials? Dr. Vivek Subbiah: Rare cancers present a perfect storm of challenges. First, the patient populations are very small, which makes it really hard to recruit enough participants for traditional type trials. Second, these patients are often geographically dispersed across multiple cities, across multiple states, across multiple countries, across multiple zip codes. So, logistics become complicated. Third, there is often limited awareness among clinicians, which delays referrals and diagnosis. Add to that regulatory hurdles, funding constraints, and you can see why rare cancer trials are so tough to execute. To overcome these barriers, we are seeing some really creative novel trial designs. And there are four different types of trial designs that are helping with enrolling patients with rare cancers. The first one is the basket trial. So let us talk about what basket studies are. Basket studies group patients based on shared genetic biomarkers or shared genetic mutations rather than tumor type. So instead of running separate 20 to 30 to 40 trials, you can study one therapy across multiple cancers. The second type of trial is the umbrella trial. The umbrella trials flip that concept of basket studies. They focus on one cancer type but test multiple targeted therapies within it. The third category of innovative trials are the platform studies. Platform trials are another exciting innovation. They allow new treatment arms to be added or removed as the data matures and as the data evolves, making trials more adaptive and efficient. The final category are decentralized tools in traditional trials, which are helping patients participate closer to where they are so that they can sleep in their own bed, which is, I think, a game changer for accessibility.  These designs maximize efficiency and feasibility for rare cancer research and rare cancer clinical trials. Dr. Hope Rugo: I love the idea of the platform trials that are decentralized. And I know that there is a trial being worked on with ARPA-H (Advanced Research Projects Agency for Health) funding in triple-negative breast cancer as well as in lung cancer, I think, and others with this idea of a platform trial. But it is challenged, I think, by precision medicine and next-generation sequencing where some patients do not have targetable markers, or there isn't a drug to target the marker. I think those are almost the same thing. We have really seen that these precision medicine ideas and NGS have moved the needle in helping to identify genetic alterations. This helps us to be more personalized. It actually helps with platform studies to customize trial enrollment. And we hope that this will result in better outcomes. It also allows us, I think, to study drugs even in the early stage setting more effectively. How can these advances be best applied to the future of rare cancers, as well as the challenges of not finding a marker or not having a drug? Dr. Vivek Subbiah: Thank you so much for that question. I think precision medicine and next-gen sequencing, or NGS, are truly the backbone of modern precision oncology. They have transformed how we think about cancer treatment. Instead of treating based on where the tumor originated or where the tumor started, we now look at the genetic blueprint of cancer. The NGS or next-gen sequencing allows us to sequence millions of DNA fragments quickly. Twenty, 30 years ago, they said we cannot sequence a human genome. Then it took almost a decade to sequence the first human genome. Right now, we have academic centers and commercial sequencing companies that are really democratizing NGS across all sites, not just in academic centers, across all the community sites, so that NGS is now accessible. This means that we can identify these actionable alterations like picking needles in haystacks, like NTRK fusions, RET fusions, or BRAF V600E alterations, high tumor mutational burden. This might occur across not one tumor type, across several different tumor types. So for rare cancers, this is critical because some of these mutations often define the best treatment option. Here is why this matters. Personalized therapy, right? Instead of a one-size-fits-all approach, we can tailor treatment to the patient's unique molecular profile. For trial enrollment, this can definitely help because patients can join biomarker-driven trials even if their cancer type is rare or ultra-rare. NGS technology has also helped us in designing rational studies. Many times monotherapy does not work in these cancers. So we are thinking about rational combination strategies. So NGS technology is helping us. Looking ahead, I see NGS becoming routine in clinical practice, not just at major niche academic centers, but everywhere. We will see more tumor-agnostic approvals, more molecular tumor boards guiding treatment decisions in real time. And I think we are seeing an expanded biomarker setup. Previously, we used to have only a few drugs and a handful of mutations. Now with homologous recombination defects, BRCA1/2 mutation, and expanding the HRD and also immunohistochemistry, we are expanding the biomarker portfolio. So again, I personally believe that the future is precision. What I mean by precision is delivering the right drug to the right patient at the right time. And for rare cancers, this isn't just progress. It is survival. And it is maybe the only way that they can have access to these cutting-edge precision medicines. Dr. Hope Rugo: That is so important. You mentioned an important area we will get to in a moment, the tumor-agnostic therapies. But as part of talking about that, do you think that the trials should also include just standard therapies? You know, who do you give an ADC to and when with these rare cancers? Because some of them do not have biomarkers to target and it is so disappointing for patients and providers where you are trying to screen a patient for a trial or a platform trial where you have one arm with this mutation, one arm with that, and they do not qualify because they only have a p53 loss, you know? They just do not have the marker that helps them. But we see this in breast cancer all the time. And it is tough because we don't have good information on the sequencing. So I wonder, you know, just because for some of these rare cancers it is not even clear what to use when with standard treatments. And then that kind of gets into this idea of the tumor-agnostic therapies that you mentioned. There are a lot of new treatments that are being evaluated. We have seen approval of some treatments in the last few years that are tumor-agnostic and based on a biomarker. Is that the best approach as we go forward for rare cancers? And what new treatment options are most exciting to you right now? Dr. Vivek Subbiah: Tumor-agnostic therapies, really close to my heart, are real breakthrough therapies and represent a major paradigm shift in oncology. Traditionally, for the broad listeners here, we are used to thinking about designing clinical trials and therapy like where the cancer originated, breast cancer, kidney cancer, prostate cancer, lung cancer. A tumor-agnostic therapy flips that model. Instead of focusing on the organ, they target the specific genetic alteration or biomarker that drives cancer growth regardless of where the tumor started, regardless of the location of the tumor, regardless of the zip code of the tumor. So why is this so important for rare cancers? Because many rare cancers share molecular features with more common cancers. For instance, NTRK fusion might occur in pediatric sarcoma, a salivary gland tumor, or a thyroid cancer. Historically, each of these would require separate trials, which is nearly impossible, unfeasible to conduct in these ultra-rare cancers like salivary gland cancer or pediatric sarcomas. Tumor-agnostic therapies allow us to treat all those cancers with the same targeted drug if they share that biomarker. Again, we are in 2025. The first tissue-agnostic approval, the historic precedent, was in fact an immunotherapy. Pembrolizumab was approved in 2017, May 2017, as the first immunotherapy to be approved in a tumor-agnostic way for a genomic biomarker, for MSI-High and dMMR cancers. Then came the NTRK inhibitors. So today we have not one, not two, but three different NTRK inhibitors: larotrectinib, entrectinib, and repotrectinib, which show response rates of nearly more than 60 to 75% across a handful of dozens and dozens of cancer types. Then, of course, we have RET inhibitors like selpercatinib, which is approved tissue-agnostic, and pralsetinib, which also shows tissue-agnostic activity across multiple cancers. And more recently, combination therapy with a BRAF and MEK combination, dabrafenib and trametinib, received tumor-agnostic approval for all BRAF V600E tumors with the exception of colorectal cancer. And even recently, you mentioned about antibody drug conjugates. Again, I think we live in an era of antibody drug conjugates. And Enhertu, trastuzumab deruxtecan, which was used first in breast cancer, now it is approved in a histology-agnostic manner for all HER2-positive tumors defined by immunohistochemistry 3+. So again, beyond NGS, now immunohistochemistry for HER2 is also becoming a biomarker. So again, for the broad listeners here, in addition to comprehensive NGS that may allow patients to find treatment options for these rare cancers for NTRK, RET, and BRAF, immunohistochemistry for HER2 positivity is also emerging as a biomarker given that we have a new FDA approval for this. So I would say personally that these therapies are game changers because they open doors for patients who previously had no options. Instead of waiting for years for a trial in their specific cancer type, they can access a treatment based on their molecular profile. I think it is precision medicine at its finest and best. Looking ahead, the third question you asked me is what is exciting going on? I think we will see more of these approvals. My hope is that today, I think we have nine to ten approvals. My hope is that within the next 25 to 50 years, we will have at least 50 to 100 drugs approved in this space based on a biomarker, not based on a location of the tumor type. Drug targeting rare alterations like FGFR2 fusions, FGFR amplifications, ALK fusions, and even complex signatures like high tumor mutational burden. I think we will be seeing hopefully more and more drugs approved. And as sequencing becomes routine, we will identify more patients for these therapies. I think for rare cancers, this is not just innovative approach. This is essential for them to access these novel precision medicines. Dr. Hope Rugo: Yeah, that is such a good point. I do think it is critical. Interestingly in breast cancer, it hasn't been, you know, there is always like two patients in these tumor-agnostic trials, or if that. You know, I think I have seen one NTRK fusion ever. I think that highlights the importance for rare cancers. And you know, I am hoping that that will translate into some new directions for some of our rarer and impossible-to-treat subtypes of breast cancer. It is this kind of research that is really going to make a difference. But what about those people who do not have biomarkers? What if you do not fit into that? Do you think there is a possibility of trying to do treatments for rare cancers in some prospective way that would help with that? You know, it is really a huge challenge. Dr. Vivek Subbiah: Absolutely. I think, you know, you're right, usually many of these rare cancers are driven by specific biomarkers. And again, some of the pediatric salivary gland tumors or pediatric sarcomas like fibrosarcomas, they are pathognomonic with NTRK fusions. And again, given that we have a tumor-agnostic approval, now these patients have access to these therapies. And I do not think that we would have had a trial just for pediatric fibrosarcomas with NTRK fusions. So that is one way. Another way is SWOG, right? The SWOG DART [1609] had this combination dual checkpoint, it was called the DART study dual combination chemotherapy with ipi/nivo. Now here the rare cancer subtype itself becomes a biomarker and they showed activity across multiple rare cancer subtypes. They didn't require a biomarker. As long as it was a rare or ultra-rare cancer, these patients were enrolled into the SWOG DART trial and multiple arms have read out. Angiosarcoma, Kaposi sarcoma, even gestational trophoblastic disease. Again, they have shown responses in these ultra-rare, rare cancers. Sometimes they might be seeing one or two cases a whole year. And I think this SWOG effort, this cooperative group effort, really highlighted the need for such studies without biomarkers as well. Dr. Hope Rugo: That is such a fantastic example of how to try and treat patients in a collaborative way. And in the paper, you also emphasize the need for collaborative research efforts, you know, uniting resource expertise across different ways of doing research. So cooperative groups, advocacy organizations that can really help advance rare cancer research, improve access to new therapies, and I think importantly influence policy changes. I think this already happened with the agnostic approvals. Could you tell us more about that? How can we move forward with this most effectively? Dr. Vivek Subbiah: Personally, I believe that collaboration is absolutely critical and essential for rare cancer research. No single institution, no single individual, or no single state or entity can tackle these challenges alone. The patient populations are small and dispersed. So pooling resources is the only way to run these meaningful trials. Again, it is not like singing, it is like putting a huge, huge, I would say, an opera piece together. It is not a solo, vocal therapy, but rather putting a huge opera piece like Turandot. You know, you mentioned cooperative groups. Cooperative groups, as I mentioned earlier, the SWOG DART program, the ASCO [TAPUR study]. ASCO is doing a phenomenal work of the TAPUR study. Again, this ASCO TAPUR program has enrolled so many patients with rare cancers who otherwise would not have treatment options. NCI-MATCH, the global effort, right? NCI-MATCH and the ComboMATCH are great examples. They bring together hundreds of sites, thousands of clinicians to run large-scale trials that would be impossible for any individual center or institution. These trials have already changed practice. For instance, the DART demonstrated the power of immunotherapy in rare cancers and influenced NCCN guidelines. One of the arms of the NCI-MATCH study from the BRAF V600E arm contributed towards the BRAF V600E tissue-agnostic approval. So, the BRAF V600E tissue-agnostic approval was by a pooled analysis of several studies. The ROAR study, the Rare Oncology Agnostic Research study, the NCI-MATCH dataset of tumor-agnostic cohort, and another pediatric trial, and also evidence from literature and evidence of case reports. And all this pooled analysis contributed to the tissue-agnostic approval of BRAF V600E across multiple rare cancers. There are several patient advocacy organizations which are the real unsung heroes here. Groups like, for instance, we mentioned in the paper, Target Cancer Foundation, don't just raise awareness for rare cancer research, they actively connect patients to trials providing financial, emotional support, and even run their own studies like the TRACK trial. They also influence policy to make access easier. On a global scale, initiatives like DRUP in the Netherlands, the ROME study in Italy, the PCM4EU in Europe are expanding precision medicine across these borders. These collaborations accelerate research, improve trial enrollment, and ensure patients everywhere can have access to these cutting-edge therapies. Again, it is truly a team effort, right? It is a multi-stakeholder approach. Researchers, clinicians, investigators, industry, regulators, academia, patients, patient advocates, and their caregivers all working together. And it takes a village. Dr. Hope Rugo: Absolutely. I mean, what a nice response to that. And I think really exciting and it is great to see your passion about this as well. But it helps all of us, I think, getting discouraged in treating these cancers to understand what is happening moving forward. And I think it is also a fabulous opportunity for our junior colleagues as they rise up in academics to be involved in these international collaborative efforts which are further expanding. One of the things that comes up for clinical trials for patients, and I think it is highlighted with rare cancers because, as you mentioned, people are all over the place, you know, they are so rare. They are all far away. Our patients are always saying to us, "Should I go here for a phase 1 trial?" Can you talk a little bit about how we can overcome these financial and geographic burdens for the patients? You talked about having trials locally, but it is a big financial and just social burden for patients. Dr. Vivek Subbiah: Great point. Financial cost is a major barrier in rare cancer clinical trials. It is a major barrier not just in rare cancer clinical trials, but in clinical trials in general. The economics of rare cancer research are one of the toughest challenges we face. Developing a new drug is already expensive, often billions of dollars. On an average, it takes 2 billion dollars or 2.8 billion dollars according to some data from drug discovery to approval. For rare cancers, the market is tiny, which means the pharmaceutical companies have really little financial incentive to invest. That is why initiatives like the Orphan Drug Act were created to provide tax credits, grants, and market exclusivity to encourage development for rare diseases. Clinical trials themselves are expensive because the small patient populations mean longer recruitment times and higher per-patient costs. Geographic dispersion, as you mentioned, for the patients adds travel, coordination. That is why we need to think out of the box about decentralized trial infrastructure so that we can mitigate some of these expenses. Complex trial designs like basket or platform trials sometimes require sophisticated data systems and regulatory oversight. That is a challenge. And I think some of the pragmatic studies like ASCO TAPUR have overcome those challenges. Advanced technologies like next-gen sequencing and molecular profiling also add significant upfront cost to this. Funding is also limited because rare cancers receive less attention compared to common cancers. Public funding and cooperative group trials help a lot, but I think they cannot cover everything. Patient advocacy organizations sometimes step in to bridge these gaps, but sustainable financing remains a huge challenge. So, the bottom line is without financial incentives and collaborating funding models, many promising therapies for rare cancers would never make it to patients. That is why we need system-wide policy changes, global partnerships, and innovative, effective, seamless trial designs which are so critical so that they can help reduce the cost and make research feasible so that we can deliver the right drug to the right patient at the right time. Dr. Hope Rugo: There is a lot of excitement about the future integration of AI in screening. Just at the San Antonio Breast Cancer meetings, we have a number of different presentations about AI to find markers, even like HER2, and using AI where you would screen and then match patients to clinical trials. Do you have any guidance for the rare cancer community on how to leverage this technology in order to optimize patient enrollment and, I think, identification of the best treatment matches? Dr. Vivek Subbiah: I think artificial intelligence, AI, is a game-changer in the making. Right now, clinical trial is clunky. Matching patients to trial is often manual, time consuming, laborious. You need a lot of personnel to do that. AI can automate this process by analyzing genomic data, medical records, and trial eligibility criteria to find the best matches quickly, accurately, and effectively. For the community, the key is to invest in data standardization and interoperability because AI needs clean, structured data to work effectively. Dr. Hope Rugo: Thank you so much, Dr. Subbiah, for sharing these fantastic insights with us on the podcast today and for your excellent article. Dr. Vivek Subbiah: Thank you so much. Dr. Hope Rugo: We thank you, our listeners, for joining us today. You will find a link to Dr. Subbiah's Educational Book article in the transcript of this episode. And please join us again next month on By the Book for more insightful views on key issues and innovations that are shaping modern oncology.  Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Hope Rugo   @hoperugo   Dr. Vivek Subbiah @VivekSubbiah Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:       Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx   Dr. Vivek Subbiah: Consulting/Advisory Role: Loxo/Lilly, Illumina, AADI, Foundation Medicine, Relay Therapeutics, Pfizer, Roche, Bayer, Incyte, Novartis, Pheon Therapeutics, Abbvie Research Funding (Inst.): Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, Abbvie, Mutlivir, Blueprint Medicines, Loxo, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Amgen, Turningpoint Therapeutics, Relay Therapeutics Other Relationship: Medscape, Clinical Care Options

(0:00) Hardy, Dan Roche & Kendra Middleton begin Hour #3 with a game brought on by Rochie.(16:08) Hardy, Rochie & Kendra go to the phone lines. Blind Scott makes an appearance. Plus, a Patriots fan talking smack to Jets fans at MetLife Stadium.(29:32) The New England Revolution take a step forward to having their new stadium project in Everett come to fruition as the Kraft Group has reached agreements with the site planning.Please note: Timecodes may shift by a few minutes due to inserted ads. Because of copyright restrictions, portions—or entire segments—may not be included in the podcast.CONNECT WITH TOUCHER & HARDY: linktr.ee/ToucherandHardyFor the latest updates, visit the show page on 985thesportshub.com. Follow 98.5 The Sports Hub on Twitter, Facebook and Instagram. Watch the show every morning on YouTube, and subscribe to stay up-to-date with all the best moments from Boston's home for sports!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(0:00) Hardy & Roche go Around The NFL: Week 18 Preview with Kendra Middleton.(11:50) Mike Dussault, content producer for Patriots.com, joins Hardy, Roche & Kendra.(27:30) THE STACK!Please note: Timecodes may shift by a few minutes due to inserted ads. Because of copyright restrictions, portions—or entire segments—may not be included in the podcast.CONNECT WITH TOUCHER & HARDY: linktr.ee/ToucherandHardyFor the latest updates, visit the show page on 985thesportshub.com. Follow 98.5 The Sports Hub on Twitter, Facebook and Instagram. Watch the show every morning on YouTube, and subscribe to stay up-to-date with all the best moments from Boston's home for sports!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(0:00) ALBERT BREER is the Senior NFL Reporter and Lead Content Strategist for The MMQB - He joins Hardy, Roche & Kendra for his weekly hour-long segment.(17:57) The panel get in to the College Football Playoffs and results over the past 2 days. Plus, Stefon Diggs & Christian Barmore in legal trouble.(36:14) The guys project the wide open AFC Playoff picture. Please note: Timecodes may shift by a few minutes due to inserted ads. Because of copyright restrictions, portions—or entire segments—may not be included in the podcast.CONNECT WITH TOUCHER & HARDY: linktr.ee/ToucherandHardyFor the latest updates, visit the show page on 985thesportshub.com. Follow 98.5 The Sports Hub on Twitter, Facebook and Instagram. Watch the show every morning on YouTube, and subscribe to stay up-to-date with all the best moments from Boston's home for sports!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Nouveaux pilotes, un brin déjantés, à bord de la Libre Antenne sur RMC ! Jean-Christophe Drouet et Julien Cazarre prennent le relais. Après les grands matchs, quand la lumière reste allumée pour les vrais passionnés, place à la Libre Antenne : un espace à part, entre passion, humour et dérision, débats enflammés, franc-parler et second degré. Un rendez-vous nocturne à la Cazarre, où l'on parle foot bien sûr, mais aussi mauvaise foi, vannes, imitations et grands moments de radio imprévisibles !

Vom geplanten Hochhaus Rankstrasse über den zweiten BIZ-Turm bis hin zum Abbruch des «Haus der Ingenieure» – 2025 war in architektonischer Hinsicht in Basel und Umgebung so einiges los: Das Jahr begann mit der Planung eines neuen Genossenschaftsquartiers in Birsfelden und endete mit der Diskussion über eine tramfreie Innenstadt. Im ArchiBasel-Podcast lassen wir 2025 Revue passieren – nicht ohne ein paar Wünsche fürs 2026... WEBSITE www.architekturbasel.ch INSTAGRAM www.instagram.com/architekturbasel FACEBOOK www.facebook.com/archibasel YOUTUBE www.youtube.com/channel/UC6hTXmiATFx-Pp6NodIBLvQ

(0:00) Still in the spirit of 2 Stats 1 Lie, Roche has a game of his own for Dondero to play.(7:07) Mike Kadlick from SI and CLNS joins the show.(24:54) Which former Patriots made the Hall of Fame finalist list?See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(0:00) Dondero and Roche continue to discuss Stefon Diggs, Drake Maye's MVP candidacy, and some hypotheticals centered on Bill Belichick.(22:36) Patriots fans weigh in on if the MVP race is over.(34:27) More from the callers.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(0:00) Andrew Callahan from the Boston Herald joins Dondero and Roche; more on the MVP race.(20:33) Discussing the biggest concern for the Patriots heading into the playoffs.(29:21) 2 Stats 1 Lie with Andrew Callahan.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Orlando Haynes speaks with Greg Roche, an entrepreneur and author of 'Fast and Easy Guide to Networking for Introverts." They discussed the challenges introverts face in networking, the importance of building a supportive network, and how to redefine networking as a giving process rather than a transactional one. Roche shares his personal journey from corporate America to becoming a networking expert, emphasizing the value of every connection, regardless of status or title. The importance of networking and building meaningful relationships, especially for introverts. He emphasizes the need for a mindset shift towards giving in networking, the value of mentorship, and the necessity of preparing one's network before it's needed. "Networking is not just for extroverts." Orlando Haynes

Le WFC distribue ses notes de Sénégal - RD Congo (1-1) & Nigeria - Tunisie (3-2), deuxième journée de la Coupe d'Afrique des Nations 2025. Osimhen vs Lookman : qui est le MVP de la journée. Quelle note pour Roche qui a apporté la première victoire en CAN dans l'histoire du Bénin ? Quelles notes pour Mendy, Koulibaly ou encore Hannibal ? 

What actually changed with David Roche's YouTube content and why did it work when so many running vlogs and films don't?In this episode of the Singletrack Podcast, I'm joined by running filmmaker and YouTube creator Jeff Pelletier for a deep, behind-the-scenes conversation about how trail running content is evolving and what Roche's Western States series revealed about the platform.We break down why YouTube rewards long-term storytelling over one-off films, how stakes and failure can be more compelling than winning, and why personality-driven channels consistently outperform brand-owned media. Jeff explains why Roche's rollout felt like a masterclass, how it changed expectations for branded content, and what brands, athletes, and creators still get wrong about YouTube.We also discuss:* Why most running brands fail on YouTube* How narrative arcs and episodic structure drive retention* The difference between short-form and long-form impact* Why YouTube is becoming the new television for endurance sports* What the next era of trail running media might look likePartners:Norda - check out the 005: the lightest, fastest, most stable trail racing shoe ever made (https://nordarun.com/)Precision Fuel and Hydration - use code SINGLETRACK at checkout for 15% off your next order (https://www.precisionhydration.com/planner/?utm_source=partner&utm_medium=podcast&utm_campaign=singletrack)Momentous - use code SINGLETRACK for up to 35% off your first order (https://livemomentous.com/) deltaG Ketones - use code Singletrack20 at checkout on their website to get 20% off your next order (https://partners.deltagketones.com/SINGLETRACK20)Raide - Making equipment for efficient human-powered movement in the mountains (https://raideresearch.com/)Gorewear - use code SINGLETRACKPOD30 at checkout on their website (bit.ly/3JVNIbL) to get 30% off your purchase.Support the show

(0:00) Mark Dondero and Dan Roche discuss everything Mike Vrabel did right in his first year coaching the Patriots.(25:43) The guys are excited the Patriots are playing important games in December again.(33:32) Will the pundits deem the Patriots a fraud team if they come up short in the playoffs?See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(0:00) Mark Dondero and Dan Roche discuss Patriots - Jets. Plus, what have been some of the biggest surprises of the NFL season?(23:37) More on the NFL including some potential playoff match ups.(32:41) Dondero and Roche finish the show with The Stack.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(0:00) Dondero and Roche list their top three Patriots wins of the season.(23:23) Dream vacations...and a few nightmare trip stories.(33:42) How did the NFL do with three games played on Christmas?See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(0:00) Michael Holley and Dan Roche discuss what could be the most significant win for the Patriots so far this season.(21:44) Holley and Roche weigh in on the importance of Mike Vrabel's messaging and culture building.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(0:00) Fred, Hardy, and everyone else from the show isn't here...but Michael Holley and Dan Roche are! Roche showed up way too early this morning wondering where everyone was...(18:43) Holley and Roche go through What Happened Last Night: Jaylen Brown and the Celtics rallied to beat the Indiana Pacers.(35:43) Philip RIvers and the Colts were routed by the San Francisco 49ers on Monday Night Football.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(0:00) Andrew Callahan from the Boston Herald joins Michael Holley and Dan Roche.(17:44) Holley, Roche, and Andrew Callahan discuss the state of the AFC and the Patriots win over the Ravens.(33:19) Can anyone figure out the lie? It's 2 Stats 1 Lie with Andrew Callahan.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(2:30) Former Patriots and Super Bowl champion Christian Fauria joins Michael Holley and Dan Roche to discuss the Patriots, why Christmas sucks, and more.(22:29) Holley and Roche do some Red Sox talk during The Stack.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Arctic is often associated with snow, ice, and tales of Santa Claus and his elves. But what if stories of Arctic elves aren't just Christmas folklore? From ancient Norse sagas to modern-day encounters, the Arctic has a surprising history of little people—beings described as small, elusive, and mysterious. In our Elf Sightings in the Arctic Christmas special, we explore historical accounts, scientific discoveries, and eyewitness testimonies that blur the line between legend and reality.Our journey begins with the Viking sagas of the 13th century, recounting events from around the year 1000. According to these sagas, Leif Erikson and his crew, after being blown off course, landed in Vinland—believed by some to be present-day Baffin Island. The Norse explorers documented encounters with people they called Skraelings, describing them as short, with tangled hair and broad faces. While historians have long assumed these were the ancestors of the Inuit, a 2008 study suggested the term Skraeling might be derived from an old Norse word for pygmy. If true, the Vikings may have believed they'd found the legendary dwarves described in ancient Greek myths—an association made even more compelling by a 1569 map labeling the North Pole as the home of pygmies, just four feet tall.The Arctic mystery deepens with the 1631 expedition of Captain Luke Foxe. While navigating the Northwest Passage, Foxe and his crew came ashore on Southampton Island. There, they discovered a strange above-ground cemetery filled with tiny coffins. The bodies inside were adult-sized but no more than four feet long, with miniature bows, arrows, and bone lances placed alongside them. Foxe, unnerved by the discovery, wrote in his journal, "God send me better adventures than these." To this day, the identity of those tiny people remains unknown.Fast forward to 1911, when Russian explorer Captain Yvolnoff led a scientific expedition into the Arctic. According to a newspaper article published in 1930, the team discovered small human footprints in the snow. Following the tracks, they found a burrow from which a tiny man emerged. He stood roughly three and a half feet tall, with an angular head and large ears. Soon, two dozen others followed, all dressed in fine animal-skin clothing. The group communicated in an unfamiliar language and lived by catching fish with their bare hands—eating only the backs and discarding the rest.Inuit oral tradition has long spoken of these tiny beings. The Inuit call them Inuaguliks or Inuarutligak—legendary dwarves who live in underground burrows, wear two sets of clothes for different tasks, and have the ability to shapeshift into animals like seals or hares. Inuit elders say these little people are playful tricksters, known to tease hunters and travel incredible distances in impossibly short amounts of time.Perhaps the most recent encounter occurred in 2017, when Anthony Roche visited his girlfriend's family cabin near Cambridge Bay, Nunavut. While napping, Roche and his girlfriend woke to the sound of footsteps on the deck. The door opened, and standing in the doorway was a tiny human figure, no taller than three feet, dressed in a ragged orange coat and caribou-skin pants. The being quickly vanished, leaving the couple bewildered. When they shared the story with their family, they were told they'd been visited by an Inuagulik.So, are these Arctic elves simply the product of myths passed down through generations? Or are these sightings evidence of something more extraordinary? From ancient Viking records to modern-day encounters, the mystery of Arctic elves endures.Join us for our festive Christmas special as we unwrap the mystery of Elf Sightings in the Arctic in our latest episode of Unsolved Canadian Mysteries, available now on Spotify and YouTube.

American conservatism as we know it today is a West Texas export, argues College of Wooster professor Jeff Roche in The Conservative Frontier: Texas and the Origins of the New Right (U Texas Press, 2025). Tracing the roots of the state's conservative movement back to the giant cattle ranches and tycoons of the nineteenth century, Roche argues that you cannot separate the local and historical conditions in the West (and in West Texas specifically) from the "cowboy conservatism" of Barry Goldwater and Ronald Reagan. Full of fascinating characters and the kind of tall tales you only find in the Lone Star State, The Conservative Frontier makes a compelling case for Texas politics eventually becoming national politics by the mid to late 20th century. No matter where you are in the United States today, the political weight of Texas creates a gravity that has proven impossible for American politics to emerge from. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/history

Die Schweizer Pharmakonzerne Roche und Novartis haben eine Vereinbarung mit den USA abgeschlossen. Gemeinsam mit sieben weiteren Pharmakonzernen verpflichten sie sich zu tieferen Medikamentenpreisen in den USA. Im Gegenzug werden sie für drei Jahren von Zöllen befreit. Doch vieles ist noch unklar. Weitere Themen: Per Gesetz musste die US-Regierung die Akten zum Fall des verurteilen Sexualstraftäters Jeffrey Epstein publizieren. Doch sie veröffentlichte erst einen Teil davon und viele sind geschwärzt. Weshalb und was weiss man nun mehr über den Missbrauchsskandal in der US-High Society? Nach Negativschlagzeilen in den Tamedia-Zeitungen reichte die Genfer Privatbank Reyl Strafanzeige ein. Damit blitzte sie nun bei der Genfer Staatsanwaltschaft ab. Ein wichtiger Entscheid im Grundsatzkonflikt zwischen Pressefreiheit und Bankgeheimnis. Und doch bleibt die Pressefreiheit unter Druck.

American conservatism as we know it today is a West Texas export, argues College of Wooster professor Jeff Roche in The Conservative Frontier: Texas and the Origins of the New Right (U Texas Press, 2025). Tracing the roots of the state's conservative movement back to the giant cattle ranches and tycoons of the nineteenth century, Roche argues that you cannot separate the local and historical conditions in the West (and in West Texas specifically) from the "cowboy conservatism" of Barry Goldwater and Ronald Reagan. Full of fascinating characters and the kind of tall tales you only find in the Lone Star State, The Conservative Frontier makes a compelling case for Texas politics eventually becoming national politics by the mid to late 20th century. No matter where you are in the United States today, the political weight of Texas creates a gravity that has proven impossible for American politics to emerge from. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

American conservatism as we know it today is a West Texas export, argues College of Wooster professor Jeff Roche in The Conservative Frontier: Texas and the Origins of the New Right (U Texas Press, 2025). Tracing the roots of the state's conservative movement back to the giant cattle ranches and tycoons of the nineteenth century, Roche argues that you cannot separate the local and historical conditions in the West (and in West Texas specifically) from the "cowboy conservatism" of Barry Goldwater and Ronald Reagan. Full of fascinating characters and the kind of tall tales you only find in the Lone Star State, The Conservative Frontier makes a compelling case for Texas politics eventually becoming national politics by the mid to late 20th century. No matter where you are in the United States today, the political weight of Texas creates a gravity that has proven impossible for American politics to emerge from. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/political-science

Richard Bonneau, Vice President of Machine Learning for Drug Discovery at Genentech and Roche, provides Pitt's HexAI podcast host, Jordan Gass-Pooré, with an insider view on how his team is fundamentally changing and accelerating how new drug candidate molecules are designed, predicted, and optimized.Geared for students in computational sciences and hybrid STEM fields, the episode introduces listeners to uses of AI and ML in molecular design, the biomolecular structure and structure-function relationships that underpin drug discovery, and how distinct teams at Genentech work together through an integrated computational system.Richard and Jordan use the opportunity to touch on how advances in the molecule design domain can inspire and inform advances in computational pathology and laboratory medicine. Richard also delves into the critical role of Explainable AI (XAI), interpretability, and error estimation in the drug design-prototype-test cycle, and provides advice on domain knowledge and skills needed today by students interested in joining teams like his at Genentech and Roche.

American conservatism as we know it today is a West Texas export, argues College of Wooster professor Jeff Roche in The Conservative Frontier: Texas and the Origins of the New Right (U Texas Press, 2025). Tracing the roots of the state's conservative movement back to the giant cattle ranches and tycoons of the nineteenth century, Roche argues that you cannot separate the local and historical conditions in the West (and in West Texas specifically) from the "cowboy conservatism" of Barry Goldwater and Ronald Reagan. Full of fascinating characters and the kind of tall tales you only find in the Lone Star State, The Conservative Frontier makes a compelling case for Texas politics eventually becoming national politics by the mid to late 20th century. No matter where you are in the United States today, the political weight of Texas creates a gravity that has proven impossible for American politics to emerge from. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/american-studies

American conservatism as we know it today is a West Texas export, argues College of Wooster professor Jeff Roche in The Conservative Frontier: Texas and the Origins of the New Right (U Texas Press, 2025). Tracing the roots of the state's conservative movement back to the giant cattle ranches and tycoons of the nineteenth century, Roche argues that you cannot separate the local and historical conditions in the West (and in West Texas specifically) from the "cowboy conservatism" of Barry Goldwater and Ronald Reagan. Full of fascinating characters and the kind of tall tales you only find in the Lone Star State, The Conservative Frontier makes a compelling case for Texas politics eventually becoming national politics by the mid to late 20th century. No matter where you are in the United States today, the political weight of Texas creates a gravity that has proven impossible for American politics to emerge from. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/american-west

American conservatism as we know it today is a West Texas export, argues College of Wooster professor Jeff Roche in The Conservative Frontier: Texas and the Origins of the New Right (U Texas Press, 2025). Tracing the roots of the state's conservative movement back to the giant cattle ranches and tycoons of the nineteenth century, Roche argues that you cannot separate the local and historical conditions in the West (and in West Texas specifically) from the "cowboy conservatism" of Barry Goldwater and Ronald Reagan. Full of fascinating characters and the kind of tall tales you only find in the Lone Star State, The Conservative Frontier makes a compelling case for Texas politics eventually becoming national politics by the mid to late 20th century. No matter where you are in the United States today, the political weight of Texas creates a gravity that has proven impossible for American politics to emerge from. Learn more about your ad choices. Visit megaphone.fm/adchoices

American conservatism as we know it today is a West Texas export, argues College of Wooster professor Jeff Roche in The Conservative Frontier: Texas and the Origins of the New Right (U Texas Press, 2025). Tracing the roots of the state's conservative movement back to the giant cattle ranches and tycoons of the nineteenth century, Roche argues that you cannot separate the local and historical conditions in the West (and in West Texas specifically) from the "cowboy conservatism" of Barry Goldwater and Ronald Reagan. Full of fascinating characters and the kind of tall tales you only find in the Lone Star State, The Conservative Frontier makes a compelling case for Texas politics eventually becoming national politics by the mid to late 20th century. No matter where you are in the United States today, the political weight of Texas creates a gravity that has proven impossible for American politics to emerge from. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/american-south

Synopsis: This episode is proudly sponsored by Quartzy. Roivant Sciences CEO Matt Gline returns to Biotech 2050 for a deeply reflective conversation with host Rahul Chaturvedi on what it really takes to build a biotech company that lasts. From Roivant's transformational $7B Pfizer-to-Roche deal to delivering registrational Phase 3 data in dermatomyositis—one of biotech's most difficult graveyard indications—Matt shares how disciplined execution, decentralization, and learning from failure shaped Roivant's trajectory. The discussion explores Roivant's unique “Vant” model, why multiple CEOs can outperform centralized command-and-control structures, and how thoughtful clinical trial design—down to steroid tapering and site execution—can make or break outcomes in rare disease development. Beyond science and strategy, Matt reflects candidly on his own evolution as CEO, the realities of leading a public biotech through volatile markets, and why authenticity, focus, and embracing hard lessons matter more than chasing hype. This episode is a masterclass in biotech leadership, clinical development, and long-term value creation. Biography: Matt Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy. Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant updates that are shaping the future of healthcare, patient care, and drug development.The U.S. Food and Drug Administration has been particularly active recently, granting Johnson & Johnson a National Priority Review Voucher for its multiple myeloma drug combination. This move highlights the importance of J&J's treatment in addressing unmet needs within oncology, a field continuously striving for innovative solutions. These vouchers expedite the review process, reflecting a broader commitment to accelerating the availability of critical therapies for patients who need them most.Continuing with regulatory advancements, AstraZeneca and Daiichi Sankyo's Enhertu, in combination with Roche's Perjeta, has gained FDA approval as a first-line treatment for unresectable or metastatic HER2-positive breast cancer. This breakthrough is supported by late-stage study results demonstrating a 44% reduction in disease progression or death compared to standard care. The approval signifies not only progress in breast cancer therapeutics but also underscores the potential benefits of strategic collaborations in drug development. Such partnerships are increasingly vital as they aim to optimize therapeutic efficacy through shared expertise and resources.In contrast to these advancements, Pfizer is facing financial recalibrations with projected revenues for 2026 estimated to decline due to diminishing COVID-19 vaccine sales and patent expirations. This situation reflects broader industry challenges as companies navigate post-pandemic market dynamics and patent cliffs, forcing reevaluations of long-term strategies.On another front, Gilead Sciences continues to push boundaries in HIV treatment with a promising single-tablet regimen combining bictegravir and lenacapavir. This innovation targets underserved segments within the HIV market, offering streamlined treatment options that could enhance patient adherence and outcomes significantly.Shifting focus to obesity management, Novo Nordisk's oral semaglutide is emerging as a highly anticipated medication among primary care providers. This trend highlights a growing preference for oral GLP-1 therapies as convenient alternatives to injectable formulations, marking a shift in how obesity—a major public health concern—is managed.The importance of regulatory compliance remains evident as Novo Nordisk received an FDA warning letter concerning manufacturing issues at an Indiana site previously owned by Catalent. This incident underscores the necessity for rigorous quality control in pharmaceutical manufacturing, which can have far-reaching implications on operational dynamics and supply chains.The FDA is also pioneering efforts to incorporate real-world evidence into medical device submissions by opening pathways for extensive deidentified datasets from sources like national cancer registries and electronic health records. This policy shift aims to integrate diverse data sources into the evidentiary foundation for medical device evaluations, potentially fostering innovation within this sector.In line with collaborative efforts, Genentech has partnered with Caris Life Sciences in a multi-year agreement valued at up to $1.1 billion, emphasizing the strategic importance of integrating diagnostic advancements with therapeutic developments to achieve precision medicine goals.Meanwhile, Yarrow Bioscience has acquired an autoimmune thyroid disease drug from China's Gensci, exemplifying a growing trend of cross-border collaborations aimed at leveraging global innovation ecosystems to address diverse therapeutic areas. This acquisition is part of a $1.37 billion deal, reinforcing the globalization of biotech partnerships as companies seek access to novel therapeutics andSupport the show

https://www.edenrafferty.com/attorneys/joseph-roche/ Visit the Howie Carr Radio Network website to access columns, podcasts, and other exclusive content.

Disconnected managers are quietly wrecking performance, culture, and execution, and most CEOs don't see it coming.In this episode, we sit down with retention and connection expert Greg Roche to unpack why manager disconnection is on the rise, how hybrid work and technology are fueling unprecedented levels of loneliness, and why authentic relationships, not perks, are the real engine of engagement.Greg shares simple, practical steps leaders can apply immediately to rebuild connection, reduce unnecessary escalations, and create an environment where people genuinely want to stay.Tune in for a conversation that will change the way you think about connection, leadership, and the future of work.⬇️ Follow The Frustrated CEO On Social⬇️LinkedIn: https://www.linkedin.com/company/the-lyons-group-consulting/TikTok:   https://www.tiktok.com/@thefrustratedceopInstagram: https://www.instagram.com/thefrustratedceopodcast/Facebook: https://www.facebook.com/people/The-Lyons-Group-Consultinginfo@thelyonsgroupconsulting.com#podcast #business #management #thefrustratedceopodcast #businessgrowthsolutions Website: Frustrated CEOSocial: LinkedIn instagram: @thefrustratedceopodcast tiktok: @thefrustratedceopodcast

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the ever-dynamic landscape of these industries, recent advancements have underscored both the scientific ingenuity and strategic foresight shaping patient care today.Pfizer has unveiled promising clinical trial data for Tukysa, indicating its potential as a first-line maintenance therapy in HER2-positive breast cancer. This development suggests that Tukysa could delay disease progression, offering patients extended survival prospects and an improved quality of life. Additionally, Pfizer's recent licensing agreement with Yaopharma for YP05002—a small molecule GLP-1 agonist currently in Phase 1 trials aimed at obesity treatment—highlights their strategic push into the rapidly evolving obesity treatment market.Meanwhile, Fondazione Telethon, an Italian nonprofit organization, has achieved a significant milestone with FDA approval for Waskyra—the first gene therapy for Wiskott-Aldrich syndrome. This ex vivo gene therapy directly targets the genetic roots of this rare disease, shifting treatment from symptomatic management to addressing underlying causes. This approval is transformative not only for patients suffering from this condition but also for the broader field of gene therapies, heralding a new era in treating rare genetic disorders.On the strategic front, Eli Lilly's decision to establish a $6 billion active pharmaceutical ingredient manufacturing facility in Huntsville, Alabama, marks a pivotal investment in U.S. manufacturing capabilities. This site will be critical in producing APIs for small molecule and peptide medicines, a testament to Lilly's commitment to meeting growing therapeutic demands while bolstering domestic production resilience—a trend gaining momentum across the industry. In oncology, Eli Lilly's Jaypirca demonstrated an impressive reduction in disease progression during Phase 3 trials for chronic lymphocytic leukemia.Biocon's acquisition of Viatris' stake in their biosimilar subsidiary exemplifies the shifting dynamics within the biosimilars market. This move allows Biocon to consolidate its market position as biosimilars gain traction as cost-effective alternatives to branded biologics. Such strategic realignments are indicative of competitive maneuvering aimed at capturing greater market share and driving down healthcare costs.Roche has made strides with compelling results from its Phase 3 trial of giredestrant, an oral selective estrogen receptor degrader showing a 30% reduction in risk for invasive breast cancer recurrence or death. The significance of this development lies in offering an oral alternative to injectable treatments, potentially improving patient adherence and reshaping standard care protocols for hormone receptor-positive breast cancer. Furthermore, Roche has achieved another regulatory milestone with its monoclonal antibody Gazyvaro gaining EU approval for treating lupus nephritis following successful Phase 3 trials.Innovation continues unabated as Formation Bio forms a new subsidiary through a $605 million deal with Lynk Pharmaceuticals. By securing rights to a next-generation immunology asset, Formation Bio positions itself at the forefront of immunological research developments. Concurrently, BioNTech and Bristol Myers Squibb have reported positive results from Phase 2 trials of Pumitamig for triple-negative breast cancer—validating bispecific antibodies' efficacy within oncology.Collaborative efforts are also reshaping industry landscapes. Bora and Corealis have partnered to create an end-to-end contract development and manufacturing organization for oral solid dose drug development. This collaboration aims to streamline processes and provide scalable solutions through a single contracting source, reflecting a shift towards integrated service models that enhance efficiencySupport the show

In this episode of The Filmumentaries Podcast, I'm joined by Laurent Hopman and Renaud Roche, the writer and artist behind the acclaimed graphic novel Lucas Wars, which tells the behind-the-scenes story of the making of Star Wars from a deeply personal, human perspective. Laurent shares his background as an entertainment journalist and how years of research, interviews, books and documentaries fed into the script. Renaud talks about coming from a traditional animation and storyboarding background, studying at Gobelins in Paris, and how cinematic visual language shaped the way he approached the book's artwork. We discuss:Why the emotional journey of George Lucas became the heart of the storyHow the pair condensed vast amounts of historical research into a tightly structured graphic novelThe challenge of visually dramatising meetings, offices and creative conflictThe relationship between Lucas and Spielberg, and how it shapes both volume one and the upcoming sequelThe meaning behind the iconic twin suns coverVisiting Skywalker Ranch and Lucasfilm after the book's releaseBalancing historical accuracy with storytellingWhy Lucas Wars connected with readers beyond the core Star Wars fandomWe also talk about the upcoming second volume, which covers The Empire Strikes Back and Raiders of the Lost Ark, and how expanding into Spielberg's world adds a new layer to the story. As always, if you enjoy the podcast and would like to support what I do, you can find me on Patreon, and the show is also available on YouTube if you prefer to watch the interviews. BUY IT HEREThis podcast is completely independent and made possible by listener support. If you'd like to help me keep making these episodes, you can join my Patreon community here: https://patreon.com/jamiebenning Watch more on YouTube:Check out the Filmumentaries YouTube channel for behind-the-scenes clips and extra content: https://youtube.com/filmumentariesAll my links

Episode 43: David Edwards — Cracking the Code on Strategic Workforce PlanningDavid Edwards has spent decades transforming strategic workforce planning from organisational afterthought into boardroom priority. Currently Head of Workforce Planning at Ericsson and founder of consultancy Dark Artistry, he's built SWP functions inside global enterprises including NatWest, where he created an internal mobility programme that saved over 500 roles from redundancy. His forthcoming book, The Strategic Workforce Planning Handbook (Kogan Page, January 2026), has earned endorsements from Dave Ulrich and David Green. In this conversation, he challenges conventional thinking about what SWP actually is—and crucially, what it isn't.What We CoverWhy SWP Remains Reactive—and How to Change ThatEdwards argues that for most organisations, SWP is still "a reactive process to the setting of budgets." The real opportunity lies in extending the window for workforce preparation—moving from crisis-mode redeployment to proactive talent readiness. At NatWest, this meant identifying at-risk employees months earlier, creating genuine career pathways rather than scrambling at redundancy notices.Planning for Strategic Workforce, Not Whole WorkforceOne standout from the recent SWP Conference was Roche's methodology: rather than planning for everyone, they focus on workforce segments that are strategically critical right now. Edwards adds a counterintuitive twist—declining workforce segments deserve equal attention, as they represent the talent pool for emerging demand.Workforce Risk as the Underused LeverWith CEO tenures averaging seven years and remuneration tied to short-term results, long-term workforce stewardship gets squeezed out. Edwards suggests reframing around risk: "What is the risk the workforce poses to the successful execution of even short-term business strategy?"The £50,000 Question: Reskilling vs RedundancyFinancial Services Skills Commission research shows reskilling saves nearly £50,000 per person compared to redundancy-and-rehire cycles. Yet most organisations default to firing. Edwards connects this to mental wellbeing—having been made redundant himself, he's passionate about proving there's a better way.Key Quote"It is not so much planning strategically for the whole workforce, but planning for the workforce which is at this moment in time strategic."Practical Tips for SWP PractitionersStart using labour market data immediately—it creates compelling stories that move business leaders.Build multiple future scenarios rather than one fragile plan.Focus on workforce segments critical to current strategy, including those in decline.Frame workforce challenges as business risk, not HR administration.What David is Working OnThe Strategic Workforce Planning Handbook publishing 3rd January 2026 (UK)—pre-order at koganpage.com/SWPHLaunching Dark Artistry consultancy offering masterclasses and advisory retainersSpeaking at People Analytics World Zurich (February 2026)About David EdwardsDavid Edwards is Head of Workforce Planning at Ericsson and founder of Dark Artistry Ltd. He previously spent over six years at NatWest building their strategic workforce management capability, and served as Advisory Services Director at Visier. A member of the Workforce Planning Institute's Global Standards Committee, he's a recognised speaker and mental health champion.Resources MentionedDeloitte Insights: Is It Time to Break Workforce Planning Out of Its Silo?McKinsey: HR's Transformative Role in an Agentic FutureFinancial Services Skills Commission: Research on reskilling cost savingsRoche and Sade Benjamin (American Airlines): SWP Conference presentationsAs ever—big thanks to our sponsors: https://lightcast.io

In episode 275 of the IDEAS+LEADERS Podcast, I'm joined by Philip Atkinson, leadership coach, organizational transformation expert, beekeeper, and author of Bee Wise: 12 Leadership Lessons from a Busy Beehive.Philip blends his experience at global organizations like Novartis, Roche, Sanofi, and Publicis with the surprising wisdom of the beehive. Together, we explore what leaders can learn from the hidden workings of a busy hive — from decision-making and communication to purpose, learning, and culture. We discuss:• Why leaders should stop being “busy as a bee”• How 50,000 bees make unanimous decisions — and how teams can too• What can we learn from bees about clear communicationIf you're a leader, manager, or entrepreneur looking for fresh, nature-rooted insights to build healthier teams and stronger organizations, this episode is for you.You can learn more about the project at https://beewisebook.com.Books can be bought at Amazon and in all book stores. ALL proceeds go to the charity, Bees For Development.Contact Philip Atkinson at Philip@Hive-Logic.comOr https://hive-logic.comOr on LinkedIn www.linkedin.com/in/philipatkinsonhivelogicThank you for joining me on this episode of IDEAS+LEADERS. If you enjoyed this episode, please share, subscribe and review so that more people can enjoy the podcast on Apple https://apple.co/3fKv9IH or Spotify https://sptfy.com/Nrtq.

Tami Roche was named Miss Burlesque in 1966 and her career took off, performing across the country and on Broadway, before moving to Atlanta in 1969 to headline at the Body Shoppe for a few weeks. Weeks turned into years and she made her way to the Domino Lounge, where she developed her famous champagne glass bath act. She even had Russ Meyer, famous sexplotation film director, write a script for her! We talked about her early childhood, her entry into burlesque, how she chose her stage name, how she became "Tassel Twirling Tami", her move to Atlanta, marriage to the club owner, his sudden death and the battle to keep and run four clubs as a woman in the 1970s. And best of all, the origin story of her famous bathtub act.  https://gofund.me/0e5816385   Want to support this podcast? Visit here Email: thevictorialemos@gmail.com Facebook | Instagram 

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über das Microsoft-Barometer und seine Folgen, das Inditex-Luxusproblem und gute Stimmung bei Salesforce. Außerdem geht es um Eli Lilly, AbbVie, Johnson & Johnson, Novo Nordisk, AstraZeneca, Abbott Laboratories, UnitedHealth Group, Bristol Myers Squibb, Dexcom, Align Technology, ResMed, Hims & Hers, JD Health International, iRhythm Technologies, Pro Medicus, Oscar Health, Xtrackers MSCI World Health Care (WKN: A113FD), Amundi S&P World Health Care Screened (WKN: A3DSTC), Franklin Future of Health and Wellness (WKN A3EFKW), Global X Telemedicine & Digital Health (WKN A2QKQ1), Xtrackers MSCI Genomic Healthcare Innovation (WKN: DBX0R2), Agilent, Roche, Vertex, Microsoft, Meta, Alphabet, Amazon, Nvidia, Salesforce, SAP, Snowflake, Inditex, H&M, Next, LVMH, Hermès, Aumovio, TKMS, Hellofresh, Gerresheimer, Ottobock, Tonies, PSI Software, Verbio, LPKF, Stratec, Thyssenkrupp Nucera, Procredit, Amadeus Fire, Bayer, BASF, Corteva, Syngenta, Formycon und PNE. Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Being a caregiver for a loved one with MS isn't an easy job. And, while it may consume hours of your time, often, it's not your only job. Many caregivers are the only family members bringing in an income. So, in addition to their caregiving responsibilities, they may also be facing the responsibilities that go along with holding down a full-time job.  This week, Diana Grazio joins me to discuss how she balances her roles and responsibilities as her partner's caregiver while holding down a full-time job.  You have online opportunities tomorrow! Participate in the National MS Society's Hispanic LatinX MS Experience Summit, or catch the International Progressive MS Alliance's global webcast, How Existing Drugs Could Transform MS Treatment. We have all the info for you to register for either or both!   If you purchase your health insurance through the ACA Healthcare Marketplace, you've probably already been notified that your premiums will skyrocket in 2026. MS Activist, Sarah Quezada, shares how those premium increases will affect her family. Roche has announced the outcomes of Phase 3 clinical trials for Fenebrutinib and Relapsing MS, and Primary Progressive MS. It's positive news, and we have the details! Could nanoparticles penetrate the blood-brain barrier and deliver anti-inflammatory medication directly to the central nervous system?  University of Illinois researchers say yes! We're sharing the details. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: It's National Family Caregiver Month  :22 The MS Care Partner Connection  :34 The National MS Society is hosting the Hispanic LatinX MS Experience Summit TOMORROW!  2:20 The International Progressive MS Alliance Global Webcast is TOMORROW!  2:51 Sarah Quezada shares how astronomical increases in ACA health insurance premiums will affect her family  3:46 Roche announces outcomes for Phase 3 clinical trials for Fenebrutinib and Relapsing MS, and Primary Progressive MS  11:59 Could nanoparticles penetrate the blood-brain barrier and deliver anti-inflammatory medication directly to the central nervous system?  13:43 Diana Grazio discusses how she manages her role as a caregiver while holding down a full-time job  16:07 Share this episode  29:10 Next week's episode  29:30 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/429 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Online Survey https://s.alchemer.com/s3/Perspectives-on-MS SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy REGISTER: The Hispanic LatinX MS Experience Summit https://nationalmssociety.org/resources/get-support/education-programs-and-library/hispanic-latinx-ms-experience REGISTER: International Progressive MS Alliance Global Webcast https://msif.org/news/2025/11/03/alliance-webcast VISIT: The MS Care Partner Connection https://mscarepartnerconnection.com STUDY: Nanoparticle-Boosted Myeloid-Derived Suppressor Cell Therapy for Immune Reprogramming in Multiple Sclerosis https://www.science.org/doi/10.1126/sciadv.ady4135 JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 429 Guests: Sarah Quezada, Diana Grazio Privacy Policy